…
Albion Technology & General VCT PLC is a venture Capital Trust specialize in early stage and growth stage investments.it prefer to invest in health tech, digital risk, Data and artificial intelligence, fintech and information technology related sector companies. It does not invest in companies that deal in property or shares and securities, banking and agriculture. It prefers to invest in technology and nontechnology-related companies based in the United Kingdom The fund seeks to invest half of the assets in quoted global technology stocks and the remaining assets in unquoted UK non-tech companies. It seeks to invest 40 percent in unquoted UK technology related companies and 60 percent in unquoted UK non-technology companies. It invests in shares or securities including loans with a five year or greater maturity period. The gross assets of a portfolio company must not exceed £15 million ($17.39 million) immediately prior to the investment and £16 million ($18.55 million) immediately thereafter. The maximum each portfolio company can receive from State Aided risk capital schemes is £5 million ($5.80 million) in aggregate from all state aided providers of risk capital, including VCTs, in the 12-month period up to and including the most recent such investment.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | 11.43M | 4.35M | -6.30M | 19.89M | -0.31M |
| Net income | 11.43M | 4.35M | -6.30M | 19.89M | -0.31M |
| Selling general administrative | 0.68M | 0.64M | 0.66M | 0.37M | 0.35M |
| Selling and marketing expenses | - | 0.64M | - | - | - |
| Gross profit | 12.51M | 0.93M | -5.64M | 20.25M | 0.04M |
| Ebit | 23.26M | 8.69M | - | 19.89M | -0.31M |
| Ebitda | 11.43M | 4.35M | -6.30M | 19.89M | -0.31M |
| Depreciation and amortization | -11.83M | -4.35M | - | - | - |
| Operating income | 11.43M | 4.35M | -6.30M | 19.89M | -0.31M |
| Other operating expenses | 6.62M | 0.30M | 0.66M | 0.37M | 0.35M |
| Interest expense | - | - | - | 0.00M | 0.00M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 2.16M | 1.61M | 1.09M | 1.06M | 0.56M |
| Net interest income | 2.16M | 1.61M | 1.09M | 1.06M | 0.56M |
| Income tax expense | - | 4.35M | - | - | - |
| Total revenue | 4.80M | 3.61M | -5.64M | 20.25M | 0.04M |
| Total operating expenses | 1.08M | 0.64M | 0.66M | 0.37M | 0.35M |
| Cost of revenue | 3.08M | 2.69M | - | - | 2.02M |
| Total other income expense net | - | 0.43M | - | - | - |
| Net income from continuing ops | 11.43M | 4.35M | -6.30M | 19.89M | -0.31M |
| Net income applicable to common shares | - | - | - | 19.89M | -0.31M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 254.14M | 128.41M | 122.35M | 107.77M | 78.64M |
| Other current assets | -0.41M | 3.43M | - | - | 2.01M |
| Total liab | 2.82M | 1.09M | 1.10M | 0.78M | 0.03M |
| Total stockholder equity | 251.32M | 127.32M | 121.25M | 106.99M | 78.03M |
| Other current liab | 0.91M | 0.94M | -0.01M | -0.78M | -0.03M |
| Common stock | 3.72M | 2.05M | 1.91M | 1.54M | 1.31M |
| Capital stock | 3.72M | 2.05M | 1.91M | 1.54M | 1.31M |
| Retained earnings | 109.83M | 108.81M | - | 52.72M | 39.64M |
| Other assets | 254.14M | 0.00M | 3.04M | 2.33M | 2.04M |
| Cash | 47.81M | 25.57M | 26.59M | 14.36M | 11.45M |
| Total current liabilities | 2.48M | 0.97M | 0.01M | 0.78M | 0.03M |
| Net debt | -47.81M | -25.57M | -26.59M | -14.36M | -11.45M |
| Other stockholder equity | 137.77M | 16.47M | 119.34M | 105.46M | 76.72M |
| Total current assets | 47.81M | 29.00M | 27.01M | 14.91M | 11.45M |
| Long term investments | 204.76M | 99.41M | 92.30M | 90.53M | 65.15M |
| Net tangible assets | - | - | - | 106.99M | 78.03M |
| Net receivables | 0.41M | 0.30M | 0.42M | 0.55M | 0.00M |
| Inventory | - | -0.30M | - | - | - |
| Accounts payable | 1.57M | 0.03M | 0.01M | 0.78M | 0.03M |
| Accumulated other comprehensive income | 0.05M | 0.00M | - | - | - |
| Common stock total equity | - | - | - | - | 1.31M |
| Non currrent assets other | -204.76M | -99.41M | -92.30M | -90.53M | -65.15M |
| Non current assets total | 204.76M | 99.41M | 92.30M | 90.53M | 65.15M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -1.39M | -1.21M | -6.58M | -4.32M | -5.61M |
| Change to liabilities | - | - | 0.00M | 0.00M | 0.00M |
| Total cashflows from investing activities | -1.39M | -1.21M | - | -4.32M | -5.61M |
| Total cash from financing activities | 24.80M | 1.72M | 20.55M | 9.08M | -13.68M |
| Net income | 11.43M | 4.35M | -6.30M | 19.89M | -0.31M |
| Change in cash | 22.24M | -1.02M | 12.23M | 2.91M | -21.02M |
| Begin period cash flow | 25.57M | 26.59M | 14.36M | 11.45M | 32.47M |
| End period cash flow | 47.81M | 25.57M | 26.59M | 14.36M | 11.45M |
| Total cash from operating activities | -1.17M | -1.54M | -6.30M | 19.89M | -1.73M |
| Issuance of capital stock | 11.41M | 10.05M | 28.48M | 15.12M | 0.00M |
| Other cashflows from investing activities | - | - | - | - | -5.61M |
| Dividends paid | 5.89M | 5.52M | 5.39M | 4.10M | 12.16M |
| Sale purchase of stock | -3.42M | -2.77M | -2.51M | -1.91M | -1.47M |
| Other cashflows from financing activities | 22.68M | -0.04M | -0.04M | -0.04M | -0.05M |
| Change to netincome | - | - | - | -21.74M | -1.42M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | - | - | - | - | -0.18M |
| Other non cash items | -1.17M | -5.88M | 6.30M | -19.89M | 0.31M |
| Free cash flow | -1.17M | -1.54M | -6.30M | 19.89M | -1.73M |
Sector: Financial Services Industry: Asset Management
|
Stock Name
|
Change
(GBX) |
Price
(GBX) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| AATG Albion Technology & General VCT PLC |
- -% |
0.64 | - | - | 51.41 | 1.04 | 198.89 |
| MNTN Schiehallion Fund Ltd |
-0.01 0.46% |
2.18 | 0.05 | - | 4.35 | 1.25 | 5.65 |
| BHMU BH Macro Limited |
- -% |
4.29 | 0.09 | - | 39.01 | 0.71 | 6.47 |
| TFG Tetragon Financial Group Ltd |
0.15 1.00% |
15.10 | 0.02 | 7.04 | 1.16 | 0.31 | 2.06 |
| BPCR BioPharma Credit PLC |
0.00 0.41% |
0.98 | 0.09 | - | 6.73 | 0.91 | 7.95 |
Albion Technology & General VCT PLC is a venture Capital Trust specialize in early stage and growth stage investments.it prefer to invest in health tech, digital risk, Data and artificial intelligence, fintech and information technology related sector companies. It does not invest in companies that deal in property or shares and securities, banking and agriculture. It prefers to invest in technology and nontechnology-related companies based in the United Kingdom The fund seeks to invest half of the assets in quoted global technology stocks and the remaining assets in unquoted UK non-tech companies. It seeks to invest 40 percent in unquoted UK technology related companies and 60 percent in unquoted UK non-technology companies. It invests in shares or securities including loans with a five year or greater maturity period. The gross assets of a portfolio company must not exceed £15 million ($17.39 million) immediately prior to the investment and £16 million ($18.55 million) immediately thereafter. The maximum each portfolio company can receive from State Aided risk capital schemes is £5 million ($5.80 million) in aggregate from all state aided providers of risk capital, including VCTs, in the 12-month period up to and including the most recent such investment.
1 Benjamin Street, London, United Kingdom, EC1M 5QL
44 20 7601 1850
| Name | Title | Year Born |
|---|---|---|
| Mr. Patrick H. Reeve A.C.A., ACA, M.A., MA | Chairman | 1961 |
| Mr. Robert Whitby-Smith ACA, BA (Hons), MSI | Partner & Investment Director | 1976 |
| Mr. Edward William Anthony Lascelles B.A., BA (Hons) | Partner | 1976 |
| Mr. William Thomas Fraser-Allen A.C.A., ACA, B.A., BA (Hons) | Deputy Managing Partner | 1972 |
| Mr. David Gudgin ACMA, BSc (Hons) | Partner and Head of Renewables | 1972 |
| Mr. Emil Gigov A.C.A., ACA, B.A., BA (Hons) | Partner | 1971 |
| Dr. Andrew Elder FRCS, M.A., MA | Partner & Head of Healthcare | 1972 |
| Dr. Christoph Ruedig M.A., M.B.A., MA, MBA | Partner | NA |
| Mr. Michael Gerald Bourne | Technology Advisor - Mang. | 1959 |
| Mr. David Gudgin A.C.M.A., B.Sc., BSc (Hons) | Partner and Head of Renewables | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.